Challenges in physician-patient communication for optimal management of systemic sclerosis-associated interstitial lung disease: a discourse analysis

Christopher P. Denton¹ · Bee Laird² · Lizette Moros³ · Jose Luis Luna Flores³

Introduction
Systemic sclerosis (SSc) is a rare, potentially life-threatening condition. The prognosis is difficult to predict, and treatment is complex. This can be difficult to understand or explain, posing challenges for effective physician-patient communication. Our study assessed communication between physicians and patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) to identify information gaps and needs.

Methods
Twenty-three 20-min consultations between physicians (rheumatologists, pulmonologists) and patients (19 real, 4 actors) with diagnosed SSc-ILD across 6 countries were observed and recorded. Interactional sociolinguistic discourse analysis was used to understand the pattern and meaning of communication, whether the needs of both participants were met, and the level of understanding between participants.

Results
In most consultations, patients were given little opportunity to explain their concerns or ask questions. Physicians used plain language but would revert to medical terminology for complex issues. Patients would also use medical terminology, despite not fully understanding the terms, which led to some physicians mistakenly believing that patients had a better understanding than they did. Differences in cognitive models between physicians and patients were often responsible for misunderstandings. However, during effective consultations, patients were invited to tell their story, and physicians used techniques to check and demonstrate understanding, express empathy and build rapport.

Conclusions
Communication challenges between physicians and patients limit joint understanding of SSc-ILD and may result in both parties misunderstanding important information and patients being less aware of self-help management approaches. Strategies should be developed with physicians to facilitate effective communication and increase patient understanding and support.

Key Points
- Physicians and patients have different explanatory models for SSc-ILD.
- The differences between the physician-constructed model of SSc-ILD and the personal model patients construct often result in misunderstandings.
- Many patients with SSc have learned the medical terminology for their condition, but their often limited understanding may lead to missed opportunities for physicians to provide clear explanations and correct misperceptions.
- The style of consultation determines the information patients share and the degree to which they feel supported by, and confident in, their physicians’ care.

Keywords
Interstitial lung disease · Patient understanding · Physician-patient communication · Systemic sclerosis

Data from this analysis were previously presented as a poster at the American College of Rheumatology and the Association for Rheumatology Health Professionals (ACR/ARHP) Annual Meeting 2017 (November 3–8, 2017 in San Diego, CA).

Christopher P. Denton
c.denton@ucl.ac.uk

¹ Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London, London, UK

² The Research Unit, Hove, UK

³ Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
Introduction

Systemic sclerosis (SSc) is a rare but severe disease in terms of the burden of symptoms on the patient, the unpredictability of prognosis and the risk of premature death [1–3]. SSc typically affects multiple organs, including the lungs, where interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) may develop. ILD (along with PAH) is now the leading cause of SSc-associated mortality [4].

In addition to the symptoms and functional limitations associated with SSc, there are other important consequences of the experience and management of the disease that negatively impact on patients. These include feelings that healthcare professionals (HCPs) have little insight into their condition and needs [5]. Studies from other chronic, unpredictably progressive diseases have illustrated the scale and complexity of communication problems that can exist between healthcare professionals and patients. An impersonal or overly clinical approach, “one-way” interactions, perceived indifference to a patient’s situation and emotions, as well as a lack of empathy, support and respect can all contribute to make the consultations a negative experience. These negative consultations can lead to patients feeling alienated and excluded from decisions about their own care [6–9].

The depth and complexity of information that patients’ desire varies widely; while some wish to be fully informed of their prognosis, others prefer less information. Ideally, the amount of information provided should be personalised, communicated in the right way, at the right time and with the appropriate people present [10]. Studies have shown negative treatment outcomes occur because of miscommunication between the physician and the patient. In contrast, patients may perceive a good or positive consultation with a physician as indicative of the quality of care they are likely to receive [11]. This has been shown in heart failure (HF) studies where empathetic conversations with physicians improved the patient’s knowledge about the disease, enabling them to better judge when they needed to seek medical help or better manage their illness [8, 12]. In addition, feeling that they have been listened to and respected by their HCP as well as being in an active partnership can enhance patients’ self-care [6].

Patients with SSc-ILD have complex needs in relation to clinical consultations and decision-making. As SSc is a rare condition, patients may perceive it as a new, mysterious illness and therefore difficult to explain [13]. The relationship between SSc and ILD may be challenging for some patients to understand [14]. The most common information needs identified by patients when asked to consider the management of this condition were understanding test results, why tests are needed, treatment options and knowing when to seek medical attention. The aim of this study was to explore the communication between physicians and patients with SSc-ILD to identify the areas of mutual understanding, the information gaps and the patient needs.

Materials and methods

This was a qualitative observational study designed to capture conversations and interactions between physicians and patients for critical discourse analysis. To ensure the natural language and intercourse between physicians and patients was captured, 20-min consultations between physicians (rheumatologists, pulmonologists) and patients with SSc-ILD in Germany, Italy, Spain, the UK and the USA were observed. In Japan, where it was not possible to include real patients, consultations were observed between real physicians and actor patients. Consultations were directly observed by an independent researcher who took no part in the consultation. These consultations took place either face to face, in a neutral setting that was hired for the purposes of the study, or by Skype call. All conversations were audio recorded and conducted in the relevant native language. In the consultation, the interactions and discussions were controlled by the physician and patient. There was no script or discussion guide.

These consultations were followed immediately with an individual in-depth interview with each participant. In each country the interviews were conducted by professional, experienced, trained qualitative interviewers who were native speakers. During the in-depth interviews, visualisation and visual metaphors were elicited to clarify the meaning of important but nebulous terms and capture the emotional meaning of SSc. Cognitive language maps formed the basis of the discussion about what was said and understood and what was misunderstood or misinterpreted, enabling the dissonance between physicians and patients to be identified and characterised.

The procedures followed in this study were in accordance with the Declaration of Helsinki. All participants provided written informed consent before taking part in the study, and all study data were held according to European Union (EU) data protection laws. The research outline was discussed with the Reading Independent Ethics Committee (UK), who advised that no ethics committee review was required. Additionally, and per the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct 2019, this research was classified as market research and therefore does not require ethics committee approval (includes Brazil, Canada, Denmark, Finland, France, Germany, Greece, Italy,
Participants

All participants were recruited using researchers based in the respective countries. Patients were recruited by physicians who verified their diagnosis of SSC-ILD.

Specialist physicians were established rheumatologists or pulmonologists with relevant specialist experience. They were required to be regularly managing patients with SSC-ILD, conducting at least one consultation every 2 months and to see four or more patients with SSC-ILD per year. Additionally, they were required to spend at least 75% of their time directly caring for patients.

Patients with SSC-ILD were diagnosed with lung involvement by a medical specialist using computer tomography (CT). Patients were required to have ILD that limited their ability to conduct moderate- or vigorous-intensity physical activity. This study included patients with a wide range of disease severities and the involvement of other organs.

None of the physicians or patients were known to one another.

Analyses

All recordings were transcribed in their native language and translated into UK English by specialist medical translators. Data from each participant was anonymised for the analysis using a numerical code (e.g. UK DR 1).

Audio recordings from each consultation were analysed using linguistic techniques based on critical discourse analysis. Specifically, three key domains were explored: (1) the pattern and meaning of communication; (2) whether the needs of both participants were met; and (3) the level of understanding between participants. More specifically, the dynamics and tone of each participant’s contribution to the conversation and the use of specific language were explored.

Each transcript was independently analysed by two experienced qualitative analysts, and their coding frames and analyses were compared. Where there was discrepancy, the analysts discussed and agreed a modified analysis. There were internal triangulation checks built into the data; both physicians and patients were asked in the interview what their understanding and experience of the consultation had been, and patients were given an opportunity to tell their unprompted stories of their SSC-ILD (which were compared with the stories they told/were able to tell in the consultation).

Results

The observed consultations

This study included 23 mock consultations between 10 rheumatologists, 8 pulmonologists, 1 dermatologist and 1 general practitioner (GP) specialising in SSC and 19 patients with SSC-ILD (Germany, 5; Italy, 4; Spain, 2; UK, 4; USA, 4) and 4 actor patients in Japan (Table 1). These consultations were conducted and observed between November 2016 and January 2017. The size of the sample was pre-determined by the rarity of the disease, and patients were selected to represent a range of severities of SSC-ILD.

The length of specialist experience amongst physicians was between 3 and 30 years, and the physicians treated an average of 32 patients with SSC-ILD every year. Patients were aged 34 to 79 years, with a disease duration of 1 to 29 years from diagnosis, and all had multiple organ involvement including the skin, hands, feet, eyes, gastrointestinal system and joints.

Analysis of the communication challenges

The analysis found that factors inhibiting effective physician-patient communication fell into three main categories: (a) consultation style, (b) meaning of language and the disconnect with use and (c) explanatory models—differences between physician and patient understanding of the disease.

Consultation style

There were three different styles of consultation:

1. An easy, flowing dialogue between patient and physician, with the physician showing good listening skills, allowing the patient to talk about the non-clinical impact of their disease as well as just the clinical aspects, and using techniques to check and demonstrate understanding, express empathy and build rapport (see Table 2 for examples of techniques used by physicians within the consultations).

2. A “Q&A” session where the physician has a list of “screening questions” to ask the patient, and they roll from one question to the next, still in a flowing discussion but with a clearer, more clinical direction. Physicians solicited the patient’s story but then quickly diverted the course of the conversation to extract clinical information from the patient. In addition, physicians sometimes asked more than one question at a time, which confused the patient and gave them the impression that the physician was in a hurry. In a few cases, physicians re-ordered the
sequence of the patient’s story as the consultation proceeded to fit their knowledge of SSc.

3. A consultation where the physician does most of the talking. Physicians use the opportunity to educate rather than to uncover the patient’s story. Occasionally, physicians asked a series of questions and then answered some of these questions for the patient without waiting for the patient’s response.

In many consultations, patients were given little opportunity to explain their concerns or ask questions. The interviewing tactics employed by many physicians during the consultations were often perceived as negative by the patients.

**Meaning of language and the disconnect with use**

When observed in this study, physicians initially used plain (lay) language in their explanations to patients but then often reverted to medical terminology when describing complex issues, for example, if they were asked to explain what SSc is and how the disease and its symptoms fit together. Physician language tended to be unemotional and matter of fact and lacking in imagery and metaphor. When metaphors were used by physicians, these helped to give patients a clearer understanding of the issue being discussed. For example, when talking about SSc, one physician described the muscle affected by SSc as being like “wood” and another described patients’ lungs as being like “darker alleys, with constriction and small spaces, and instead of a balloon that you can push on, there are just more rigid walls, with some very narrow areas”.

Patients’ language tended to be functional and factual, unless the physician demonstrated emotional empathy, which elicited more emotional language from the patient. Overall, the patient tone was physician led and was influenced by the questions the physician asked and the way the physician asked these questions. The focus of the discussion was on providing information the physician was seeking rather than allowing the patient to share their whole story. During the consultation, patients often used medical terms but had limited understanding of the meaning. This sometimes led to the physician thinking the patient had a better understanding of issues around SSc than was the case and providing further information in very medical terms which patients struggled to understand. Table 3 provides examples of patients’ use of medical terminology which led physicians to believe they had a better understanding of their SSc-ILD than they actually did. There was also a disconnect in the terminology used around the disease, with physicians using the words “systemic sclerosis” while patients preferred “scleroderma”.

**Explanatory models—differences between physician and patient understanding of the disease**

Explanatory models, first described by the physician and medical anthropologist Arthur Kleinman, are the cognitive models we build to explain and make sense of illness. Explanatory models are not diagnostic tools but can provide physicians with an idea of how patients experience and interpret their conditions [16].

---

**Table 1** Overview of the research sample

| Location | Patients (n) | Physicians (n) | Face to face interviews | Patients (n) | Physicians (n) |
|----------|--------------|----------------|-------------------------|--------------|----------------|
| Germany  | 5            | 2 rheumatologists | 5                      | 2 rheumatologists |
|          |              | 1 pulmonologist  |                         | 1 pulmonologist |
|          |              | 1 dermatologist  |                         | 1 dermatologist |
|          |              | 1 general practitioner (GP) | | 1 GP |
| Italy    | 4            | 3 rheumatologists | 4                      | 3 rheumatologists |
|          |              | 1 pulmonologist  |                         | 1 pulmonologist |
| Spain    | 2            | 2 pulmonologists | 2                      | 2 pulmonologists |
| UK       | 4            | 1 rheumatologist | 4                      | 0a           |
| USA      | 4            | 2 rheumatologists | 4                      | 2 rheumatologists |
|          |              | 2 pulmonologists |                         | 2 pulmonologists |
| Japan    | 4b           | 2 rheumatologists | 0b                     | 2 rheumatologists |
|          |              | 2 pulmonologists |                         | 2 pulmonologists |

a No physician interviews were conducted in the UK. The same rheumatologist “consulted” all 4 patients

b As patients were not available, actors were used to play the part of patients with SSc-ILD in Japan
Physicians have their own explanatory model that is largely based on the medical model/understanding of disease, reflecting their professional knowledge and experience; this usually determines the questions physicians ask and how they interpret the answer patients give them. Patients’ explanatory models are built on personal knowledge, beliefs and experiences of illness and determine how patients make sense of the disease and treatment information provided by their physicians. As a result, there is often a discrepancy between patients’ and physicians’ explanatory models that explains why there are misunderstandings and why some patients reject medication or refuse to comply with a prescribed therapy.

Physicians and patients have different ways of understanding SSc-ILD, based on their knowledge, experiences, expectations and personal beliefs (Fig. 1). These determined what information the patient shared and how they interpreted information provided by their physician. Patients’ understanding of what SSc-ILD is and what causes it is often different from the medical model of the disease. Beliefs about causes, symptoms and transmissibility were often only partly correct or based upon misconceptions. Even patients who had been diagnosed for many years had a limited understanding of the disease process and how their symptoms fitted together. Differences in the explanatory models used by physicians and patients were responsible for these misunderstandings. Most patients thought the cause of SSC and SSc-ILD was genetic and that it was triggered by stress or illness. Many of the symptoms were described in detail by patients, with some references made to connective tissue and fibrosis. However, there was generally a superficial or self-constructed understanding of how it all fitted together.

**Similarities and differences between countries**

The range of consultation styles was observed across all of the countries with the exception of Japan, where the consultations all followed the pattern of a “Q&A” session, with the physician directing the consultation using more technical medical language. Patients’ use of language and terms to describe their SSc-ILD and symptoms was universal; the same or similar terms were used across all countries, and there were no differences between countries in the terms used by physicians.

| Table 2 | Direct quotes from physicians and patients made during and immediately after the consultation |
| --- | --- |
| **Empathy** | Patient: “Yes, I kind of get, you know, all the symptoms possible.” |
|  | Physician: “A little overwhelming, I’m sure, right?” |
| **Rapport building** | Patient: “Do you live by yourself or with family?” |
|  | Physician: “I live with my daughter, my 17-year-old.” |
|  | Physician: “That’s a headache. I’m sorry, I have kids too.” |
|  | Patient: “Oh my God. I agree, totally. I just cannot wait until she’s off to college. I mean, I need a vacation.” |
|  | Physician: “Okay, uh-oh. I will not tell her you said that.” |
| **Consultation pattern (patient quotes)** | “He was talking non-stop.” |
|  | “He had his things to say. He did not stop to listen to what I was saying.” |
|  | “Sometimes I see him writing in [sic] the computer and he asks, ‘And how have you been?’ And he keeps writing.” |
| **Use and meaning of language during the consultation (patient quotes)** | “If [doctors] use technical terms, it’s beyond me, but a lot of them do that… It used to be like that—I went to lots of doctors, and they told me all sorts of things, but I did not know what they meant, but then I found out for myself.” |
|  | “Of course [the doctor] assumed a lot of knowledge in me, about scleroderma… and also the lung involvement, he also used many specialist terms like fibrosis, lung fibrosis, of course he also wanted a lot of specialist knowledge from me.” |
| **Understanding of SSc-ILD (patient quotes)** | “[The doctor] said it is a congenital disease, it is not because of something I had done or had not done to develop this disease; she said that the body itself rejects those cells or something like that…” |
|  | “My body produces too much collagen, it’s hard to explain. There are deposits and that is what causes everything to swell, especially the oesophagus, it gets narrower. [The lungs] harden because of the collagen deposits, they get swollen, and this stops them from working properly.” |
Table 3 Examples of patients’ use of medical terminology leading physicians to think they have a better understanding of their SSc-ILD than they actually have

| Example 1 | Language the patient used in the consultation: |
|-----------|-----------------------------------------------|
|           | • CellCept mycophenolate                        |
|           | • CAT scan                                      |
|           | • Early mild fibrosis                           |
|           | • Discoid lupus                                 |
|           | • Hypothyroidism                                |
|           | • Pernicious anaemia                            |
|           | • Raynaud’s syndrome                            |
|           | • Vitiligo                                      |

Physician feedback from consultation: “She seems knowledgeable. She seemed informed about the tests that were done, the reasons that things were done and the reason things were started and stopped”.

This is the patient’s understanding/explanation for her scleroderma: “What’s going on inside is that some of my cells have gone berserk. They’re supposed to do certain things: They’re supposed to keep my skin smooth. They’re supposed to oil my skin. They’re supposed to keep it soft and moist. They’re supposed to protect it from the outside environment. Those cells have lost their mind and they are now attacking myself, as if I am an enemy”.

Example 2

What the patient said in the consultation: “I have GERD and as far as the symptoms of that go, the only thing I think that is troublesome for me is malnutrition. I have Sjögren’s so I have the dry eyes and mouth. Scleroderma’s my primary and Raynaud’s and Sjögren’s were definitely secondary. I’m taking CellCept and methotrexate”.

Physician feedback from the consultation: “I think my role as a physician is to educate. I mean, doctor means teacher. So just educating her about her disease—which she seemed very knowledgeable about”.

This is the patient’s understanding/explanation of her scleroderma: “I do not want to blame my pregnancy for triggering something. It’s so weird how I do not know if I want to say my pregnancy definitely triggered it or brought it out more—but they cannot—oh, of course they can say what it was really [the cause of her scleroderma], but I also do believe that it’s probably from both my parents’ genetics.

I think that’s another reason why I probably cannot gain weight, because the skin is so tight. I think it’s the overproduction of collagen is affecting the tissue. I mean I lost my muscle. I do not have a lot of that muscle left”.

### Discussion

This study identified three key domains of physician-patient communication that can impact positively or negatively on the SSc-ILD patient’s experience of clinical consultations. Physicians who controlled the consultation and did not allow patients time to ask their own questions contributed to a negative experience. The language used by physicians significantly influenced how patients felt about the consultations; a lack of warmth and empathy created distance between participants, while the use of metaphors encouraged more patient engagement. Notably, despite using medical terminology, patients often did not know what it meant. Physicians therefore assumed patients were more knowledgeable than they were and explained things in a complex manner that patients failed to understand. Using empathy and building rapport was welcomed by patients and led to a more positive consultation experience.

Patients with SSc need to feel confident about their interactions with physicians, and this depends on the physician’s medical and interpersonal skills, including their ability to individualise the relationship [13]. Findings from this study are consistent with other studies of physician-patient communication within consultations and their impact on emotional well-being. Both a lack of empathy from HCPs and their unwillingness to discuss aspects not specifically related to SSc have previously been cited by patients as a great source of emotional distress [17]. Additionally, patient’s dissatisfaction has been shown to relate to the absence of a holistic approach to care and due to a lack of tact by physicians, who they felt had little interest in their suffering [13]. Literature on chronic illness generally supports rapport building as a crucial step in fostering trust between physicians and patients [18]. Not being “present” and attentive to patient needs can lead to a focus on issues that are not important to the patient. Allowing patients a time to tell their story if they need to may encourage a more positive experience. The degree of patient participation in consultations has been shown to be specifically related to physicians’ verbal and non-verbal encouragement and reflection of facts and emotions [19]. In patients with HF, negative feelings following conversations with certain physicians resulted in wariness about future consultations and a lack of confidence in the physician [20]. As in this study in SSc-ILD, other studies have shown that patients with HF did not get the opportunity to ask questions, often because they perceived the physician to be too busy and
because they did not feel empowered to start this kind of discussion [21]. However, a physician carefully exploring and respecting a patient’s hopes, fears and goals can ensure that the consultation is a positive experience for the patient [22].

The communication experience between the physician and patient can have both direct and indirect influences on outcomes. In patients with HF, face-to-face conversations with HCPs rather than by telephone have been shown to be associated with a decrease in hospital readmissions [23]. Health outcomes are also affected indirectly, including patient-enhanced satisfaction with care and empowerment, improved motivation regarding adherence and self-care, and increased knowledge and self-efficacy [24, 25].

Forming a therapeutic partnership with the physician is vital to many patients who have serious and chronic illnesses. This can facilitate the physician’s understanding of the patient’s wishes and beliefs while also identifying any misconceptions about the illness and its management [24]. It has been shown that in patients with bowel or breast cancer, a physician’s empathy is associated with shared decision-making and reduces any regret the patient might have about the treatment choices they have made [26]. Conversely, less participation than the patient wanted was associated with a higher level of regret regarding treatment decisions. Similar findings have been reported in patients with multiple sclerosis (MS) in terms of their choice of disease-modifying therapy [27]. Negative communication experiences have led to some patients with MS perceiving their neurologists as having little interest in their day-to-day ongoing difficulties and stress [28, 29].

Language, or rather the use of medical terminology during patient consultations, is a common problem throughout medicine. In a study of rheumatology consultations, although almost 80% of physicians did not explain the medical words they used, patient responses did not indicate whether they had understood [30]. As in our study, many patients began using the same words and phrases for themselves in the discussion. Inappropriate language can substantially impact patients. For example, if a patient with HF is told he is failing drug therapy, he will most likely blame himself, even if this was not the physician’s intention [22].

Poor understanding of their disease can lead to uncertainty, anxiety, fear and even disappointment for patients, including those with SSc-ILD [14, 31]. Indeed, it has been shown that patients with SSc were fearful when their symptoms progressed but remained unexplained by HCPs [32]. One study highlighted SSc patients’ misunderstanding of the disease that are similar to those in our study and included personal views about the causes of SSc [13].

There are many key positive and negative factors identified in this study that could improve future consultations between

---

**Fig. 1** Physician and patient explanatory models in SSc

| PHYSICIAN MODEL | PATIENT MODEL |
|-----------------|---------------|
| • Cause of SSc is not completely understood | • SSc is due to genetics, and is triggered by stress or illness |
| • Pathogenesis explanations are sometimes incomplete | • Describes the symptoms well but lacks deep understanding |
| • Emphasis on the causative agents can differ | • Unpredictability is threatening |
| • Aware of the full range of symptoms but the onset can be insidious | • Initial symptoms were accommodated as ageing, tiredness, family etc. Serious symptoms appeared suddenly |
| • Often frustrated by the lack of treatment options, where none can really make a difference to the outcome | • Seek help when the symptoms can’t be tolerated |
| • No treatments that they can have confidence in | • Expectations of treatments are low. Side effects often outweigh benefits and there is a fear of what will come next |
| • The disease is unpredictable and difficult to manage | • Impact of the condition is widespread and devastating |
| • Outcomes are poor, often fatal, causing a sense of helplessness because current treatments are inadequate | • Some are proactive and others overwhelmed. Patients cope through acceptance but fear the inevitable deterioration |
| • Metaphors are more complex and can reflect the symptoms and pathology | • Uses very negative, threatening, or frightening metaphors |

---

Clin Rheumatol
physicians and patients. Although patients expect physicians to be knowledgeable about their condition, they also need them to be human and attentive. Honest and empathetic two-way communication between physicians and patients is critical and can help to mitigate potential feelings of devastation when receiving diagnoses in SSC. Recognising each patient’s experience of their disease as unique is paramount to successful consultation. Consistent strategies therefore need to be codeveloped and implemented in order to facilitate effective communication and provide support, increase patients’ understanding of SSc-ILD and ultimately improve the patient experience.

Acknowledgements The authors would like to thank the participants who took part in this research. This study was designed by Hamell Communications (London, UK) in collaboration with Boehringer Ingelheim. Hamell Communications conducted the study in collaboration with Professor Denton.

Data availability. To ensure independent interpretation of clinical study results, Boehringer Ingelheim grants all external authors access to all relevant material, including participant-level clinical study data, and relevant material as needed by them to fulfil their role and obligations as authors under the ICMJE criteria.

Furthermore, clinical study documents (e.g. study report, study protocol, statistical analysis plan) and participant clinical study data are available to be shared after publication of the primary manuscript in a peer-reviewed journal and if regulatory activities are complete and other criteria are met per the BI Policy on Transparency and Publication of Clinical Study Data: https://trials.boehringer-ingelheim.com/transparency_policy.html

Prior to providing access, documents will be examined and, if necessary, redacted, and the data will be de-identified, to protect the personal data of study participants and personnel and to respect the boundaries of the informed consent of the study participants.

Clinical Study Reports and Related Clinical Documents can be requested via this link: https://trials.boehringer-ingelheim.com/trial_results/clinical_submission_documents.html

All such requests will be governed by a Document Sharing Agreement.

Bona fide, qualified scientific and medical researchers may request access to de-identified, analysable participant clinical study data with corresponding documentation describing the structure and content of the datasets. Upon approval, and governed by a Data Sharing Agreement, data are shared in a secured data-access system for a limited period of 1 year, which may be extended upon request.

Researchers should use https://clinicalstudydatarequest.com to request access to study data.

Funding information The study was funded by Boehringer Ingelheim. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no compensation related to the development of the manuscript. Writing support was provided by Alison Carr, PhD, of Hamell Communications, and editorial support was provided by Islay Steele, PhD, of Nucleus Global, both contracted and funded by Boehringer Ingelheim International GmbH. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

Compliance with ethical standards

Conflict of interest C Denton reports grants and personal fees from GSK, personal fees from Boehringer Ingelheim, grants and personal fees from Inventiva, personal fees from Actelion, grants and personal fees from CSL Behring, personal fees from Bayer, personal fees from Roche, personal fees from Sanofi, during the conduct of the study. L Moros, and JL Luna Flores are employees of Boehringer Ingelheim. B Laird was a contractor to Boehringer Ingelheim at the time this research was conducted.
Ethics approval The procedures followed in this study were in accordance with the Declaration of Helsinki. All participants provided written informed consent before taking part in the study, and all study data were held according to European Union (EU) data protection laws. The research outline was discussed with the Reading Independent Ethics Committee (UK), who advised that no ethics committee review was required. Additionally, and per the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct 2019, this research was classified as market research and therefore does not require ethics committee approval (includes Brazil, Canada, Denmark, Finland, France, Germany, Greece, Italy, Japan, Mexico, the Netherlands, Norway, Poland, Russia, South Korea, Spain, Sweden, Turkey, the UK and the USA).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cossu M, Beretta L, Mosterman P, de Hair MJH, Radstake TRDJ (2018) Unmet needs in systemic sclerosis understanding and treatment: the knowledge gaps from a scientist’s, clinician’s, and patient’s perspective. Clin Rev Allergy Immunol 55(3):312–331. https://doi.org/10.1007/s12016-017-8636-1
2. Nihtianova SL, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, Wells AU, Denton CP (2014) Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 66(6):1625–1635. https://doi.org/10.1002/art.38390
3. Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thoms BD (2010) Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology. 50(4):762–767. https://doi.org/10.1093/rheumatology/keq310
4. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815. https://doi.org/10.1136/ard.2009.114264
5. Sumpton D, Thakkur V, O'Neill S, Hennessy S, Groom D, Craig JC, Tong A (2017) "It’s not me, it’s not really me." Insights from patients living with systemic sclerosis: an interview study. Arthritis Care Res (Hoboken) 69(1):1733–1742. https://doi.org/10.1002acr.23207
6. Currie K, Strachan PH, Spaling M, Harkness K, Barber D, Clark AM (2014) The importance of interactions between patients and healthcare professionals for heart failure self-care: a systematic review of qualitative research into patient perspectives. Eur J Cardiovasc Nurs 14(6):525–535. https://doi.org/10.1177/1474515114454768
7. Klindworth K, Oster P, Hager K, Krause O, Bleidorn J, Schneider N (2015) Living with and dying from advanced heart failure: understanding the needs of older patients at the end of life. BMC Geriatrics 15:125. https://doi.org/10.1186/s12877-015-0124-y
8. Mead H, Andres E, Ramos C, Siegel B, Regenstein M (2010) Barriers to effective self-management in cardiac patients: the patient’s experience. Patient Educ Couns 79(1):69–76. https://doi.org/10.1016/j.pec.2009.08.003
9. Pietrolongo E, Giordano A, Kleinefeld M, Convalonieri P, Lugaresi A, Tortorella C et al (2013) Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. PloS One 8(4):e60721-e. https://doi.org/10.1371/journal.pone.0060721
10. Etiknd SN, Bristowe K, Bailey K, Selman LE, Murtagh FE (2017) How does uncertainty shape patient experience in advanced illness? A secondary analysis of qualitative data. Palliat Med 31(2):171–180. https://doi.org/10.1177/02692161316647610
11. Baudendistel I, Noest S, Peters-Klumm F, Herzberg H, Scherer M, Blozik E, Joos S (2015) Bridging the gap between patient needs and quality indicators: a qualitative study with chronic heart failure patients. Patient Prefer Adherence 9:1397–1405. https://doi.org/10.2147/PPA.S83850
12. Clark AM, Savard LA, Spaling MA, Heath S, Duncan AS, Spiers JA (2012) Understanding help-seeking decisions in people with heart failure: a qualitative systematic review. Int J Nurs Stud 49(12):1582–1597. https://doi.org/10.1016/j.ijnurstu.2012.05.010
13. Mouthon L, Alami S, Boisard A-S, Chaigne B, Hachulla E, Poiraudoue S (2017) Patients’ views and needs about systemic sclerosis and its management: a qualitative interview study. BMC Musculoskelet Disord 18(1):230. https://doi.org/10.1186/s12891-017-1603-4
14. Mittoo S, Frankel S, LeDage S, Strand V, Shah AA, Christopher-Stine L, Danoff S, Hummers LK, Swigris JJ, Huscher D, Christensen AM, Cenac SL, Erbil JK, Ferguson S, Garcia-Valladares I, Grewal HK, Orbai AM, Smith KC, Tran M, Bingham CO 3rd, Castelino FV, Fischer A, Saketkoo LA (2015) Patient perspectives in OMERACT provide an anchor for future metric development and improved approaches to healthcare delivery in connective tissue disease related interstitial lung disease (CTD-ILD). Curr Respir Med Rev 11(2):175–183. https://doi.org/10.2147/1573398X116615019182624
15. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA (2014) Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 89(9):1245–1251. https://doi.org/10.1097/ACM.0000000000000388
16. Kleiman A (1980) Patients and healers in the context of culture: an exploration of the borderland between anthropology, medicine, and psychiatry. University of California Press, Berkeley
17. Gumuchian ST, Peláez S, Delisle VC, Carrier M-E, Jewett LR, El-Baaliabi G et al (2016) Exploring sources of emotional distress among people living with scleroderma: a focus group study. PloS One 11(3):e0152419. https://doi.org/10.1371/journal.pone.0152419
18. Mauksch LB, Dugdale DC, Dodson S, Epstein R (2008) Relationship, communication, and efficiency in the medical encounter: creating a clinical model from a literature review. JAMA Intern Med 168(13):1387–1395. https://doi.org/10.1001/archinte.168.13.1387
19. Zandbelt LC, Smets EMA, Oort FJ, Godfried MH, de Haes HCJM (2007) Patient participation in the medical specialist encounter: does physicians’ patient-centred communication matter? Patient Educ Couns. 65(3):396–406. https://doi.org/10.1016/j.pec.2006.09.011
20. Fry M, McLachlan S, Purdy S, Sanders T, Kadam UT, Chew-Graham CA (2016) The implications of living with heart failure: the impact on everyday life, family support, co-morbidities and access to healthcare: a secondary qualitative analysis. BMC Fam Pract 17(1):139. https://doi.org/10.1186/s12875-016-0537-5
21. Harding R, Selman L, Beynon T, Hodson F, Coady E, Read C et al (2008) Meeting the communication and information needs of chronic heart failure patients. J Pain Symptom Manag 36(2):149–156. https://doi.org/10.1016/j.jpainsymman.2007.09.012

22. Kelemen AM, Ruiz G, Groninger H (2016) Choosing words wisely in communication with patients with heart failure and families. Am J Cardiol 117(11):1779–1782. https://doi.org/10.1016/j.amjcard.2016.03.003

23. Sochalski J, Jaarsma T, Krumholz HM, Laramee A, McMurray J, Naylor MD, Rich MW, Riegel B, Stewart S (2009) What works in chronic care management: the case of heart failure. Health Aff 28(1):179–189. https://doi.org/10.1377/hhaff.28.1.179

24. Street RL, Makoul G, Arora NK, Epstein RM (2009) How does communication heal? Pathways linking clinician–patient communication to health outcomes. Patient Educ Couns. 74(3):295–301. https://doi.org/10.1016/j.pec.2008.11.015

25. Michie S, Miles J, Weinman J (2003) Patient-centredness in chronic illness: what is it and does it matter? Patient Educ Couns. 51(3):197–206. https://doi.org/10.1016/S0163-4827(02)00194-5

26. Nicolai J, Buchholz A, Seefried N, Reuter K, Härter M, Eich W et al (2016) When do cancer patients regret their treatment decision? A path analysis of the influence of clinicians’ communication styles and the match of decision-making styles on decision regret. Patient Educ Couns. 99(5):739–746. https://doi.org/10.1016/j.pec.2015.11.019

27. Tintoré M, Alexander M, Costello K, Dddy M, Jones DE, Law N, O’Neill G, Uccelli A, Weissert R, Wray S (2016) The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence 11:33–45. https://doi.org/10.2147/PPA.S115090

28. Dennison L, McCloy Smith E, Bradbury K, Galea I (2016) How do people with multiple sclerosis experience prognostic uncertainty and prognosis communication? A qualitative study. PloS One 11(7):e0158982. https://doi.org/10.1371/journal.pone.0158982

29. Senders A, Sando K, Wahbeh H, Peterson Hiller A, Shinto L (2016) Managing psychological stress in the multiple sclerosis medical visit: patient perspectives and unmet needs. J Health Psychol 21(8):1676–1687. https://doi.org/10.1177/1359105314562084

30. Koch-Weser S, Dejong W, Rud R (2009) Medical word use in clinical encounters. Health Expect 12(4):371–382. https://doi.org/10.1111/j.1369-7625.2009.00555.x

31. Lambrinou E, Protopapas A, Kalogirou F (2014) Educational challenges to the health care professional in heart failure care. Curr Heart Fail Rep 11(3):299–306. https://doi.org/10.1007/s11897-014-0203-y

32. Nakayama A, Tunnichiffe DJ, Thakkar V, Singh-Grewal D, O’Neill S, Craig J et al (2016) Patients’ perspectives and experiences living with systemic sclerosis: a systematic review and thematic synthesis of qualitative studies. J Rheumatol. 43(7):1363. https://doi.org/10.3899/jrheum.151309

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.